Segment Transport Versus Acute Shortening In The Treatment of Tibial Pseudarthroses With Bone Loss

This study has been completed.

Sponsor:

Information provided by:

Bezmialem Vakif University

ClinicalTrials.gov Identifier:

NCT01246934

First received: November 23, 2010

Last updated: NA

Last verified: November 2010

History: No changes posted

Tracking Information
First Received Date ^ICMJE	November 23, 2010
Last Updated Date	November 23, 2010
Start Date ^ICMJE	October 2009
Primary Completion Date	December 2009 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: November 23, 2010)	TREATMENT PERIOD AND COMPLICATION RATE
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Segment Transport Versus Acute Shortening In The Treatment of Tibial Pseudarthroses With Bone Loss
Official Title ^ICMJE	Not Provided
Brief Summary	In this study the investigators are presenting the advantages as well as the disadvantages of ACUTE SHORTENING AND RELENGTHENINIG VS SEGMENT TRANSPORT methods.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Not Provided
Study Design ^ICMJE	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment
Condition ^ICMJE	TIBIA PSEUDOARTHROSES
Intervention ^ICMJE	Other: ASR METHOD
Study Arm (s)	No Intervention: COMPLICATION Intervention: Other: ASR METHOD
Publications *	Paley D, Sen C, Tetsworth K. Acute Shortening With Subsequent Relengthening Versus Bone Transport In The Treatment Of Tibial Bone Defect, 11th Asami North America Annual Scientific Meeting, February 18-25, Berkeley Ca, 2001
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	22
Completion Date	February 2010
Primary Completion Date	December 2009 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria:TIBIA PSEUDOARTHROSES - Exclusion Criteria:BONE LOSS GREATER THAN 10 CM -
Gender	Both
Ages	13 Years to 50 Years
Accepts Healthy Volunteers	Not Provided
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Turkey

Administrative Information
NCT Number ^ICMJE	NCT01246934
Other Study ID Numbers ^ICMJE	BVUORT001
Has Data Monitoring Committee	No
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Bezmialem Vakif University
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Bezmialem Vakif University
Verification Date	November 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top